Tools
Stock profile

Elanco Animal Health Inc (ELAN)

ELAN · Latest close $26.70 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$26.70
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
3
vs previous quarter

Elanco Animal Health Inc (ELAN) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($935.9K bought vs $100.0K sold). Latest close $26.70 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 15, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $835.9K
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Winslow Capital Management · Dodge & Cox Funds · Maverick Capital — 3 tracked funds hold ELAN. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $935.9K) vs 1 sale ($100.0K). Latest buy: Aug 20, 2026. Insider trading

Often held alongside

ANALOG DEVICES INC (ADI) · GE Vernova Inc. (GEV) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Winslow Capital Management1.14%13,511,127TRIMMED (-0.8%) Q3 filed Nov 12
Dodge & Cox Funds0.87%67,397,025TRIMMED (-2.2%) Q3 filed Nov 13
Maverick Capital0.02%98,098TRIMMED (-32.1%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +7.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

26.847.352024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding518 of 8,857 filers
Long-only filers among them516
Change vs 2026 Q1+14 net · 495 entered · 481 exited
Shares reported, all filers566,623,465
Reported value, all filers$13.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$4.7B
Net income · FY2025$-232.0M
Total assets · FY2025$13.4B
Shares outstanding499,621,830
Market cap (at latest close)$13.3B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.

Short interest

Shares short · Oct 15, 202631,106,655
Share of shares outstanding6.23%
Days to cover6.39

Shares short at recent settlements — Jul 31, 2026: 36.0M · Aug 14, 2026: 29.7M · Aug 31, 2026: 30.9M · Sep 15, 2026: 31.8M · Sep 30, 2026: 37.3M · Oct 15, 2026: 31.1M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 369 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $935.9K), against 1 sale by 1 insider ($100.0K). Latest buy: Aug 20, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Kurzius Lawrence Erik · 40,000 shares on Aug 20, 2026 · filed Aug 21, 2026$23.40+5.9% (close Aug 24, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Aug 24, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 15, 2026Bettington Timothy JSEE REMARKSSell4,350$23.00$100.0KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 11, 2025Todd S and Jennifer G Young Living Trust Dtd 08/03/2021Former CFO49,333$830.0KAug 11, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 14, 2026Dimensional Fund Advisors LPSC 13G25,417,2715.1%Jun 30, 2026SEC filing
May 14, 2026Dodge & CoxSC 13G/A68,944,10013.9%Mar 31, 2026SEC filing
May 13, 2026PRIMECAP MANAGEMENT CO/CA/SC 13G/A45,840,9569.2%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G26,138,9905.2%Mar 31, 2026SEC filing
Apr 9, 2026Dimensional Fund Advisors LPSC 13G/A24,527,1354.9%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 13, 2026Dodge & CoxSC 13G/A79,084,30515.9%Dec 31, 2025SEC filing
Feb 5, 2026FMR LLCSC 13G/A52,196,321.3810.5%Dec 31, 2025SEC filing
Jan 21, 2026Dimensional Fund Advisors LPSC 13G25,082,5455.0%Dec 31, 2025SEC filing
Nov 14, 2025T. Rowe Price Investment Management, Inc.SC 13G31,547,9706.4%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 199 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Animals (169), Agriculture (117), Trade (domestic/foreign) (104).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 5 · Buy txns: 5 · Buy value: $1.5M · Latest buy: Aug 20, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 5 of the last 20 quarterly lists; latest 2025 Q4, ranked #16 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Share count tripled (3x)10.0%-6.4%-8.2%+1.8%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold ELAN — ranked by lift, the co-holding pattern described in Methodology: ANALOG DEVICES INC (ADI) · GE Vernova Inc. (GEV) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN).

6 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 6, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
May 27, 20265.07 Submission of Matters to a Vote of Security HoldersSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ANALOG DEVICES INC (ADI) · Track Record: how the signals scored · Practice timing on ELAN

One email a week: the week’s new filings and research. Subscribe free

← EL  ·  ELF →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.